Immunotherapy is part of multimodal treatment for distantly metastatic head and neck squamous cell carcinoma (mHNSCC); however, survival outcomes outside of clinical trials have not been systematically assessed.
This study used the US National Cancer Database (NCDB) to evaluate the use and outcomes of nonpalliative immunotherapy across various HNSCC primary sites outside of clinical trial settings.
